title: A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
authors: V
authors: V
authors: Sardnal
authors: A
authors: A
authors: Rouquette
authors: S
authors: S
authors: Kaltenbach
authors: C
authors: C
authors: Bally
authors: V
authors: V
authors: Chesnais
authors: C
authors: C
authors: Leschi
authors: L
authors: L
authors: Ades
authors: V
authors: V
authors: Santini
authors: S
authors: S
authors: Park
authors: A
authors: A
authors: Toma
authors: P
authors: P
authors: Fenaux
authors: F
authors: F
authors: Dreyfus
authors: M
authors: M
authors: Fontenay
authors: O
authors: O
authors: Kosmider
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D002872:Chromosome Deletion; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D010447:Peptide Hydrolases / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D012306:Risk; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D044767:Ubiquitin-Protein Ligases
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; C502543:CRBN protein, human; D013792:Thalidomide; D044767:Ubiquitin-Protein Ligases; D010447:Peptide Hydrolases; D000077269:Lenalidomide